Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06943157

Self-Efficacy and Medication Adherence in Patients With Coronary Artery Disease: A Descriptive Study

This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Data will be collected using a Descriptive Information Form, the Self-Efficacy for Managing Chronic Disease Scale, and the Medication Adherence Report Scale (MARS).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Adiyaman University Training and Research Hospital

Adıyaman, 02040, Turkey (Türkiye)

Location status: Recruiting

Location contact

Ayla YAVA, Professor, PhD

SUB_INVESTIGATOR

Aynur KOYUNCU, Assistant Professor

SUB_INVESTIGATOR

Nuran TOSUN, Professor, PhD

SUB_INVESTIGATOR

Zeynal KİZİR, PhD Student

CONTACT

[email protected]

+905446445202

Zeynal KİZİR, PhD Student

PRINCIPAL_INVESTIGATOR

About this study

Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Managing CAD requires long-term treatment adherence and lifestyle changes. Self-efficacy, which reflects an individual's belief in their ability to perform specific health behaviors, plays a key role in disease management. In CAD patients, high levels of self-efficacy have been associated with better treatment adherence, improved symptom management, and successful adoption of healthy behaviors.

This descriptive study is designed to investigate the relationship between self-efficacy and medication adherence in individuals diagnosed with CAD. The study will be carried out at Adıyaman University Training and Research Hospital between March and October 2025. The target population includes patients who have been diagnosed with CAD (e.g., angina pectoris, myocardial infarction) for at least one year and meet the inclusion criteria. Based on a power analysis using G*Power software (effect size f² = 0.15, α = 0.05, power = 0.90), the required sample size is calculated as 112. However, accounting for possible data loss or participant dropout, the final sample size is set at 135.

Data collection tools include:

Descriptive Information Form to assess demographic and clinical characteristics,

The 6-Item Self-Efficacy for Managing Chronic Disease Scale, validated in Turkish by İncirkuş and Özkan Nahcivan (Cronbach's alpha = 0.90),

Medication Adherence Report Scale (MARS), adapted to Turkish by Temeloğlu Şen et al. (Cronbach's alpha = 0.78).

The findings are expected to contribute to the literature and guide healthcare professionals, particularly nurses, in planning educational and counseling services to improve self-efficacy and medication adherence among CAD patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Being 18 years of age or older

Having been diagnosed with Coronary Artery Disease (angina pectoris, unstable angina, myocardial infarction) at least 1 year ago

Being followed

Being able to communicate in Turkish

Voluntarily agreeing to participate in the study

Having no diagnosed mental disorder

Exclusion criteria

  • Having a primary diagnosis other than Coronary Artery Disease

Being unable to complete the questionnaires due to mental health problems

Providing incomplete data or withdrawing from the study

Treatment and study plan

No intervention

Other

This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment.

Primary outcomes

  1. Self-efficacy score for chronic disease management

    Time frame: At the time of data collection (March 2025 - October 2025)

    Self-efficacy levels of patients with coronary artery disease will be measured using the 6-Item Self-Efficacy Scale for Chronic Disease Management. Each item is rated from 1 to 10. The total score ranges from 6 to 60, and higher scores indicate better self-efficacy in chronic disease management.

Secondary outcomes

  1. Medication adherence score

    Time frame: At the time of data collection (March 2025 - October 2025)

    Patients' adherence to their prescribed medication regimen will be assessed using the Medication Adherence Report Scale (MARS). The MARS scale ranges from 5 to 25, with higher scores indicating better medication adherence.

Study contacts

Contact information is provided by the study sponsor or research team.

ZEYNAL KİZİR, PhD Student

CONTACT

[email protected]

+9005446445202 ext. +9005446445202

Sponsors and collaborators

Lead sponsor

Hasan Kalyoncu University

Other

Registry information

Official study title

Investigation of the Relationship Between Self-Efficacy and Adherence to Medication in Individuals With Coronary Artery Disease: A Descriptive and Correlational Study

Acronym: SEMACAD

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 24, 2025
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.